C9orf72 promoter hypermethylation is neuroprotective

Neurology

Volumn 84, Issue 16, 2015, Pages 1622-1630

  McMillan, Corey T ^a,c   Russ, Jenny ^a   Wood, Elisabeth M ^c   Irwin, David J ^a,c   Grossman, Murray ^a   McCluskey, Leo ^b   Elman, Lauren ^b   Van Deerlin, Vivanna ^c   Lee, Edward B ^a  

^a Center for Neurodegenerative Disease Research   (United States)

^b PENNSYLVANIA HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CLINICAL EXAMINATION; DNA METHYLATION; FEMALE; FRONTAL CORTEX; GRAY MATTER; HIPPOCAMPUS; HUMAN; MALE; NEUROIMAGING; NEUROPATHOLOGY; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN READING FRAME; PRIORITY JOURNAL; PROMOTER REGION; THALAMUS; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN CORTEX; CROSS-SECTIONAL STUDY; FRONTAL LOBE; FRONTOTEMPORAL DEMENTIA; GENETICS; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY;

C9ORF72 PROTEIN, HUMAN; PROTEIN; REPETITIVE DNA;

AMYOTROPHIC LATERAL SCLEROSIS; CEREBRAL CORTEX; CROSS-SECTIONAL STUDIES; DNA METHYLATION; DNA REPEAT EXPANSION; FEMALE; FRONTAL LOBE; FRONTOTEMPORAL LOBAR DEGENERATION; GRAY MATTER; HIPPOCAMPUS; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; PROTEINS; THALAMUS;

EID: 84928139474     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001495     Document Type: Article

References (39)

1. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245-256.
2. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257-268.
3. Mackenzie IRA, Frick P, Neumann M. The neuropathology associated with repeat expansions in the C9ORF72 gene. Acta Neuropathol 2014;127:347-357.
4. Wood EM, Falcone D, Suh E, et al. Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. JAMA Neurol 2013;70:1411-1417.
5. Boxer AL, Gold M, Huey E, et al. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement 2013;9:189-198.
6. Xi Z, Rainero I, Rubino E, et al. Hypermethylation of the CpG-island near the C9orf72 G4C2-repeat expansion in FTLD patients. Hum Mol Genet 2014;23:5630-5637.
7. Russ J, Liu EY, Wu K, et al. Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. Acta Neuropathol 2015;129:39-52.
8. Liu EY, Russ J, Wu K, et al. C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD. Acta Neuropathol 2014;128:525-541.
9. Bede P, Bokde AL, Byrne S, et al. Multiparametric MRI study of ALS stratified for the C9orf72 genotype. Neurology 2013;81:361-369.
10. Bede P, Elamin M, Byrne S, et al. Basal ganglia involvement in amyotrophic lateral sclerosis. Neurology 2013;81:2107-2115.
11. Boxer AL, Mackenzie IR, Boeve BF, et al. Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry 2011;82:196-203.
12. Byrne S, Elamin M, Bede P, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol 2012;11:232-240.
13. Irwin DJ, McMillan CT, Brettschneider J, et al. Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2013;84:163-169.
14. Mahoney CJ, Downey LE, Ridgway GR, et al. Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions. Alzheimers Res Ther 2012;4:41.
15. Brettschneider J, Van Deerlin VM, Robinson JL, et al. Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. Acta Neuropathol 2012;123:825-839.
16. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456-2477.
17. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006-1014.
18. Strong MJ, Grace GM, Freedman M, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009;10:131-146.
19. Libon DJ, Rascovsky K, Gross RG, et al. The Philadelphia Brief Assessment of Cognition (PBAC): a validated screening measure for dementia. Clin Neuropsychol 2011;25: 1314-1330.
20. Avants BB, Libon DJ, Rascovsky K, et al. Sparse canonical correlation analysis relates network-level atrophy to multivariate cognitive measures in a neurodegenerative population. Neuroimage 2014;84:698-711.
21. Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal 2008;12:26-41.
22. Avants BB, Tustison NJ, Song G, Cook PA, Klein A, Gee JC. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage 2011;54:2033-2044.
23. Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp 2002;15:1-25.
24. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273-289.
25. McMillan CT, Avants BB, Cook P, Ungar L, Trojanowski JQ, Grossman M. The power of neuroimaging biomarkers for screening frontotemporal dementia. Hum Brain Mapp 2014;35:4827-4840.
26. Belzil VV, Bauer PO, Gendron TF, Murray ME, Dickson D, Petrucelli L. Characterization of DNA hypermethylation in the cerebellum of c9FTD/ALS patients. Brain Res 2014;1584:15-21.
27. Xi Z, Zinman L, Moreno D, et al. Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. Am J Hum Genet 2013;92:981-989.
28. Whitwell JL, Weigand SD, Boeve BF, et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain 2012;135:794-806.
29. Mahoney CJ, Beck J, Rohrer JD, et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain 2012;135:736-750.
30. Raz N, Lindenberger U, Rodrigue KM, et al. Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. Cereb Cortex 2005;15:1676-1689.
31. Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013;74:20-38.
32. Davidson YS, Barker H, Robinson AC, et al. Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol Commun 2014;2:70.
33. Whitwell JL, Jack CR, Senjem ML, et al. MRI correlates of protein deposition and disease severity in postmortem frontotemporal lobar degeneration. Neurodegener Dis 2009;6:106-117.
34. Cooper-Knock J, Hewitt C, Highley JR, et al. Clinicopathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain 2012;135:751-764.
35. Mackenzie IR, Arzberger T, Kremmer E, et al. Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol 2013; 126:859-879.
36. McMillan CT, Toledo JB, Avants BB, et al. Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration. Neurobiol Aging 2014;35:1473-1482.
37. Premi E, Formenti A, Gazzina S, et al. Effect of TMEM106B polymorphism on functional network connectivity in asymptomatic GRN mutation carriers. JAMA Neurol 2014;71:216-221.
38. Premi E, Gazzina S, Bozzali M, et al. Cognitive Reserve in granulin-related frontotemporal dementia: from preclinical to clinical stages. PLoS One 2013;8:e74762.
39. Belzil VV, Bauer PO, Prudencio M, et al. Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol 2013;126:895-905.